"Asthma and COPD drugs market by Disease and Medication Class: Global Opportunity Analysis and Industry Forecast, 2021-2030", the asthma and COPD drugs market size was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64% from 2021 to 2030.
Download Sample Report : https://www.alliedmarketresearch.com/request-sample/311
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the asthma and COPD drugs market as most hospitals are not operating due to COVID-19 and the ongoing lockdowns in many countries. The COVID-19 virus has serious and life-threatening impact on patients with respiratory disorders. However, a huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for the patient diagnosed with COVID-19, and this is expected to increase the diagnosis and treatment of respiratory diseases, which contributes in the market growth.
Asthma is respiratory condition marked by attacks of spasm in the bronchi of lungs, causing difficulty in breathing. It is usually connected to allergic reactions or other forms of hypersensitivity. COPD is a group of respiratory diseases, in which there is constriction of airways and difficulty or discomfort in breathing.
The asthma and COPD can be prevented and treated with drugs such as corticosteroids, short-acting beta agonists, and anticholinergic drugs. In the acute asthmatic attack, patient feels difficulty to breathe due to sudden narrowing of bronchi, generally due to allergens. In acute asthmatic attack, bronchodilators give quick relief and can be life saving for patients.
Key Market Players
Abbott Laboratories
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Glaxosmithkline Plc
Hoffmann-La Roche Ltd
Novartis AG
Organon
Sanofi
Teva Pharmaceutical Industries Ltd
Vectura Group Plc
Key Findings Of Study
On the basis of diseases, the asthma segment was the highest contributor to the market in 2020.
On the basis of medication class, combination drug segment dominated the market in 2020.
On the basis of region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
North America accounted for a majority of the global asthma and COPD drugs market share in 2020, and is anticipated to remain dominant during the forecast period. Asia-Pacific is anticipated to witness lucrative growth, owing to the increase in number of asthma and COPD patients.
Key Market Segments
BY DISEASES
Asthma
COPD
BY MEDICATION CLASS
Combination Drugs
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Leukotriene Antagonists (LTA)
Anticholinergics
Others
Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/311
Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.
Global Asthma and COPD Drugs Market: Information by Disease (COPD and Asthma), Product (Long-Term Asthma Control Medications, Quick Relief Medications), Route of Administration (Oral, Inhaled), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027Market HighlightsGlobal Asthma and COPD Drugs Market are expected to register a CAGR of 7.90% during the forecast period with a market value of USD 43,444.72 Million till 2025.
COPD or chronic obstructive pulmonary disease is an umbrella term used for a group of respiratory diseases such as emphysema and chronic bronchitis.Segment AnalysisThe Global Asthma and COPD Drugs Market have been segmented by disease, product, route of administration, and distribution channel.
Anticholinergics is further sub-segmented into Spiriva and others.
On the basis of the distribution channels, global asthma and COPD drugs market has been segmented into retail pharmacies, hospital pharmacies, and online pharmacies.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8749Regional AnalysisGlobal asthma and COPD drugs market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas are likely to dominate global asthma and COPD drugs market.
According to the American Academy of Allergy Asthma & Immunology, in 2016, approximately 8.3% of children in the US had asthma.
Moreover, the rising health expenditure per person and increasing demand for advanced treatment options are also expected to drive market growth.The European market for asthma and COPD drugs is expected to be the second-largest during the review period.
Asthma and COPD Drug Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the asthma and copd drug market market include Mylan, Aerovance Inc. Alkermes Inc. Almirall SA.
Genentech Inc. Sepracor, Inc. Skyepharma plc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Asthma and COPD Drug Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/asthma-and-copd-drug-market/download-sampleMarket DynamicsThe advancement in the medical sciences and technology and the heavy investment of the giant drug and pharmaceutical companies have been producing pioneer therapies and drugs for treating asthma and COPD since the late twentieth century.
High prevalence of asthma and COPD, generation of innovative medicines and their approval by the Food and Drug Administration (FDA), and massive patients of asthma and COPD receiving the treatment accelerate the growth of the drug markets.
